Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

Paxlovid isn't the only antiviral medication for COVID-19. Merck’s Lagevrio is another available pill, though it's proven to be less popular in the U.S. than Paxlovid. A third drug, Gilead's ...

Paxlovid reduced the COVID-19 death rate in high-risk patients by 73%, according to an NIH study. ... Yet treatment must begin when symptoms are mild or moderate, the CDC says.

Dr. Astha Muttreja, a physician at the Stony Brook Medicine's post-COVID Clinic in Lake Grove, said there had been “cautious optimism” that Paxlovid would be a potential treatment method for ...

FDA revises emergency use authorization for Pfizer's Paxlovid, impacting distribution and treatment of mild-to-moderate COVID-19. Transitions from March 8.

Taking the COVID-19 antiviral Paxlovid does not appear to improve Long COVID symptoms in a meaningful way, a new study finds. Those results are a blow to the millions of people living with the ...

"If you want to create a barrier to people getting a treatment, ... Pfizer reported $12.5 billion in Paxlovid and COVID vaccine sales in 2023, after a $57 billion peak in 2022.

In her Jan. 17 op-ed, “Our biggest covid policy failure,” Leana S. Wen wondered why only about 15 percent of high-risk patients with covid-19 get prescribed or take Paxlovid. And the Jan. 16 ...

When Paxlovid was first authorized for emergency use in the U.S. in December 2021, it was free for anyone who needed it. Once the government stopped funding the treatment, Pfizer set a list price ...